13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000078003
Total reported value
$170.4M
$170.4M
18 檔
106.8%
According to the latest 13F quarterly dataset, Pfizer Inc managed an equity portfolio of $170.4M at the end of Q4 2025, spanning 18 distinct U.S. exchange-listed positions.
In Q4 2025, Pfizer Inc adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 18.60% | -22.05% | — | |
| 2 | ARVN | Arvinas Inc | Stock-Other | 17.34% | +1.61% | — | |
| 3 | CELC | Celcuity Inc | Stock-Other | 14.74% | +4.22% | — | |
| 4 | WVE | Wave Life Sciences Ltd. | Stock-Other | 13.48% | +1.42% | — | |
| 5 | ALLO | Allogene Therapeutics Inc | Stock-Other | 12.76% | +6.70% | — | |
| 6 | ✓ | Zura Bio LTD | Stock-Other | 6.58% | -5.36% | — | |
| 7 | PYXS | Pyxis Oncology Inc | Stock-Other | 3.42% | +7.57% | — | |
| 8 | CRBU | Caribou Biosciences Inc | Stock-Other | 3.15% | +1.13% | — | |
| 9 | CRDF | Cardiff Oncology Inc | Stock-Other | 2.87% | +0.20% | — | |
| 10 | BHVN | Biohaven Ltd. | Stock-Other | 2.41% | +2.93% | — | |
| 11 | SPRO | Spero Therapeutics Inc | Stock-Other | 2.33% | +0.82% | — | |
| 12 | NXTC | Nextcure Inc | Stock-Other | 0.95% | -0.60% | — | |
| 13 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.54% | +1.42% | — | |
| 14 | QTTB | Q32 Bio Inc | Stock-Other | 0.39% | -0.31% | EXIT | |
| 15 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 16 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.07% | +0.02% | — | |
| 17 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.01% | +0.01% | — | |
| 18 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.01% | — | -95.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CELC | Celcuity Inc | +10.8% | — | Unchanged |
| 2 | ARVN | Arvinas Inc | +10.6% | — | Unchanged |
| 3 | WVE | Wave Life Sciences Ltd. | +10.3% | — | Unchanged |
| 4 | ALLO | Allogene Therapeutics Inc | +6.5% | — | Unchanged |
| 5 | ORIC | Oric Pharmaceuticals Inc | +3.9% | — | Unchanged |
| 6 | ✓ | Zura Bio LTD | +3.6% | — | Unchanged |
| 7 | CRDF | Cardiff Oncology Inc | +1.7% | — | Unchanged |
| 8 | SPRO | Spero Therapeutics Inc | +1.3% | — | Unchanged |
| 9 | NXTC | Nextcure Inc | +0.7% | — | Unchanged |
| 10 | BHVN | Biohaven Ltd. | +0.7% | — | Unchanged |
| 11 | CRBU | Caribou Biosciences Inc | +0.7% | — | Unchanged |
| 12 | QTTB | Q32 Bio Inc | +0.3% | — | Unchanged |
| 13 | ZNTL | Zentalis Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 14 | ANTX | An2 Therapeutics Inc | +0.1% | — | Unchanged |
| 15 | BOLT | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 16 | SENS1GBP | Senseonics Holdings Inc | 0% | -95.00% | Trim |
| 17 | DNA | Ginkgo Bioworks Holdings Inc | — | — | Unchanged |
| 18 | PYXS | Pyxis Oncology Inc | -0.2% | — | Unchanged |
| 19 | BNTX | Biontech Se-adr | — | EXIT | Sold out |
| 20 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 21 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Pfizer Inc reported a total U.S. public equity portfolio value of $170.4M across 18 disclosed positions in Q4 2025.
During Q4 2025, Pfizer Inc's top holdings by market value included ORIC (18.6%)、ARVN (17.3%)、CELC (14.7%). The largest single position, ORIC, represented 18.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ORIC, ARVN, CELC) accounted for 106.8% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
BNTX
前期市值: $163.5M
In Q4 2025, Pfizer Inc made 4 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.